Aristo Pharma Nordic ApS: Financial statements 2018
CVR: 32328768
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
Aristo Pharma Nordic ApS (CVR 32328768) has filed annual accounts for 2018. In 2018, the company reported a gross profit of EUR -948,611 and a net result of EUR -1,875,856 compared with EUR -5,014,436 the year before. Equity in the 2018 report amounted to EUR -3,049,848. The company had 8 employees in the financial year.
- Gross Profit
- EUR -948,611
- Profit/Loss
- EUR -1,875,856
- Equity
- EUR -3,049,848
- Total Assets
- EUR 3,003,504
- Employees
- 8
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | - | -949 t. EUR | -1.9 mio. EUR | -3 mio. EUR | 8 |
| 2017 | - | -3.9 mio. EUR | -5 mio. EUR | -1.2 mio. EUR | 10 |
| 2016 | - | -475 t. EUR | -2.1 mio. EUR | -4.7 mio. EUR | 12 |
| 2015 | - | 145 t. EUR | -1.6 mio. EUR | -2.7 mio. EUR | 11 |
| 2014 | - | -734 t. EUR | -1.7 mio. EUR | -1.1 mio. EUR | 12 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
Aristo Pharma Nordic ApS has published its annual report for 2017. Gross profit came to DKK -3,906,558, and the net result was DKK -5,014,436.
About Aristo Pharma Nordic ApS
Aristo Pharma Nordic ApS is a Danish company of the type Anpartsselskab based in Skovlunde, founded in 2011. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The company was previously named AMNEAL NORDIC ApS and COPHARMA ApS. The management consists of John Hudson Kriwet. The board consists of John Hudson Kriwet (chair), Jannes Paul Beeskow and Robert Maciej Szymanski. The company is owned by Aristo Pharma GmbH. The company has 1 employee (2026). In 2025, the company reported revenue of EUR 453,392 and a net result of EUR 21,589 compared with EUR 25,190 the year before. Equity in the 2025 report amounted to EUR 184,874.